linjc16/ctgov huggingface dataset:
Effect of Hyoscine- Bromide on Duration of the First Stage of Labor

Study Overview
=================
Brief Summary
-----------------
Spasmolytic drugs are frequently used in delivery rooms to overcome cervical spasms and thus reduce the duration of labor. The aim of this randomized double blind placebo controlled trial is to study the efficacy of hyoscine butylbromide (HBB) for shortening of the first stage of labor in primigravid women.

Official Title
-----------------
Effect of Hyoscine- Bromide on Duration of the First Stage of Labor

Conditions
-----------------
Labor

Intervention / Treatment
-----------------
* Drug: hyoscine butylbromide
* Other: normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primigravid women. Singleton pregnancy. Presenting by the vertex. Gestational age between 37 and 42 weeks In active phase of labor with a cervical dilatation between 4-5 cm, with either intact membranes or spontaneous rupture of membranes for less than 12 h Exclusion Criteria: Previous uterine scarring. Malpresentation. Antepartum hemorrhage. Labor induction Contraindication to vaginal delivery. Contraindication to hyoscine.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: buscopan group<br>will receive 2 ml (40 mg) of hyoscine butylbromide | Drug: hyoscine butylbromide<br>* will be given during first stage of labor intravenously<br>|
| Placebo Comparator: control group<br>will receive 2 ml of normal saline | Other: normal saline<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration of first stage of labor | duration | 6 months |
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis

Official Title
-----------------
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: Oral EP262
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year BSA of 3% to 20% and a vIGA-AD score of ≥3 Exclusion Criteria: Other active skin diseases associated with chronic pruritus Clinically infected atopic dermatitis that requires antibiotic therapy Use of specific treatments for atopic dermatitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EP262 150 mg<br> | Drug: Oral EP262<br>* Once daily<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Once Daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of EP262 | Assessed by the incidence of treatment-emergent adverse events | Measured from Day 1 to End of Study or Early Termination (Up to 10 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of EP262 on skin histology | Assessed by changes in epidermal thickness and immune cell infiltration from skin biopsy sample | Measured from Day 1 to Week 6 | 
| Effect of EP262 on skin gene expression | Assessed by RNA sequencing of skin biopsy samples | Measured from Day 1 to Week 6 |
Quadratus Lumborum Plain Block Versus Fascia Iliac Block

Study Overview
=================
Brief Summary
-----------------
evaluation the efficacy of Quadratus Lumborum plain Block Versus Fascia Iliac Block for postoperative pain after hip surgery

Official Title
-----------------
Quadratus Lumborum Plain Block Versus Fascia Iliac Block in Hip Fracture

Conditions
-----------------
Post Operative Pain

Intervention / Treatment
-----------------
* Procedure: Quadratus Lumborum plain Block
* Procedure: fascia iliaca block
* Diagnostic Test: control group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-70 years fracture hip Exclusion Criteria: patients refuse mental problem patient with any coagulation deficiency or bleeding problems patient with allergy to investigated medications,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Quadratus Lumborum Block<br> | Procedure: Quadratus Lumborum plain Block<br>* ultrasound guided Quadratus Lumborum plain Block using 0.5 ml/kg bupivacaine 0.25% .<br>|
| Experimental: Fascia Iliac Block<br> | Procedure: fascia iliaca block<br>* ultrasound guided fascia iliaca block using 0.5 ml/kg bupivacaine 0.25%<br>|
| Active Comparator: control<br> | Diagnostic Test: control group<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| analgesic consumption | intraoperative and post operative | 24 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analogue pain score | score 0-10 which mean 0 no pain and 10 the worst pain | 24 hour | 
| first analgesic demand | the first time to intake rescue analgesia | 24 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
QLB, Fascia Iliac Block, hip surgery
Inulin Supplementation in Patients With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the glycemic and metabolic control of type 1 diabetic patients in replacement therapy with insulin, comparing those treated with a supplementation of prebiotics (inulin) and those treated with a placebo. Therefore, the primary objective of the study is represented by the proportion of patients with better glycemic control (basal and post-prandial euglycemia time) and optimal metabolic control (HbA1c, lipid profile, C-RP).

Official Title
-----------------
Efficacy Evaluation of Inulin Supplementation on Metabolic Control and Akkermansia Muciniphila Levels in Patients With Type 1 Diabetes: a Pilot Study

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Dietary Supplement: inulin
* Other: standard therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with T1D, diagnosed before 35 years of age will be enrolled Exclusion Criteria: advanced complications of T1D (established renal failure, severe retinopathy and diabetic neuropathy) BMI> 30 kg / m2.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: inulin supplementation<br> | Dietary Supplement: inulin<br>* patients treated with standard therapy with a supplementation of Inulin 6g twice a day for 3 months.<br>|
| Active Comparator: standard therapy<br> | Other: standard therapy<br>* control group (patients treated also with standard therapy)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glycemic control | represented by the proportion of patients with better glycemic control (basal and post-prandial euglycemia time) and optimal metabolic control (HbA1c, lipid profile, C-RP). | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| akkermania levels | evaluate the presence of Akkermansia in the gut microbiota at enrollment, and to compare its quantitative modification from the beginning to the end of the therapy, comparing inulin vs a control group. | 3 months |
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone

Study Overview
=================
Brief Summary
-----------------
Adult subjects with elevated intraocular pressure who have successfully undergone placement of iStent infinite trabecular bypass system will be randomized to receive a travoprost intraocular implant or receive a sham procedure and be followed for 12 months.

Official Title
-----------------
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite vs. iStent Infinite Alone in Subjects With Open-angle Glaucoma or Ocular Hypertension

Conditions
-----------------
Glaucoma, Open-Angle

Intervention / Treatment
-----------------
* Drug: Travoprost Intraocular Implant
* Other: Sham procedure
* Device: iStent infinite


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of open-angle glaucoma or ocular hypertension qualifying IOP in the study eye Exclusion Criteria: unmedicated (washed out) IOP of >36 mmHg in the study eye hypersensitivity to travoprost or any other components of the travoprost intraocular implant vertical cup/disc ratio > 0.8 in the study eye best spectacle corrected visual acuity of worse than 20/80 in either eye eye any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: iDose TR<br>Travoprost Intraocular Implant in subjects who had successful iStent infinite placement | Drug: Travoprost Intraocular Implant<br>* anchored intracameral implant containing travoprost in subjects who successfully received iStent infinite<br>* Other names: iDose TR;Device: iStent infinite<br>* Successful iStent infinite surgery<br>|
| Sham Comparator: sham procedure<br>Sham surgical procedure in subjects who had successful iStent infinite placement | Other: Sham procedure<br>* Sham procedure (to mimic placement of travoprost intraocular implant) in subjects who successfully received iStent infinite<br>Device: iStent infinite<br>* Successful iStent infinite surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from baseline in mean diurnal intraocular pressure (IOP) | mean diurnal IOP at the 3 month visit minus mean diurnal IOP at baseline | 3 months |
Diagnostic Precision Study on Vibration Induced Nystagmus Test for SCDS by Ortofone B250 Skull Vibration Protocol

Study Overview
=================
Brief Summary
-----------------
to study the videonystagmography response to a bone conducted vibration on the mastoid by B250 bone transducer in patients affected by vestibular loss, Menieres disease and Superior Semicircular Canal Dehiscence Syndrome vs healthy control subjects

Official Title
-----------------
Diagnostic Precision Study on Vibration Induced Nystagmus Test for SCDS by Ortofone

Conditions
-----------------
Superior Canal Dehiscence Syndrome, Vestibular Disorder

Intervention / Treatment
-----------------
* Diagnostic Test: vibration induced nystagmus test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients affected by certain vestibular disorders. Exclusion Criteria: Patients with vertigo and dizziness without certain diagnosis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Vestibular disorders<br>Patients uppfilling vestibular disorders diagnostic criterias | Diagnostic Test: vibration induced nystagmus test<br>* Vibration induced nystagmus test by bone transducer B250.<br>|
| Other: healthy control subjects<br>Patients without past or ongoing vestibular or balance disorders | Diagnostic Test: vibration induced nystagmus test<br>* Vibration induced nystagmus test by bone transducer B250.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measure of eye movements | angular velocity of eye movements during skull vibration. | through study completion, an average of 18 months |
Research Participation With Transgender and Gender-Diverse Youth

Study Overview
=================
Brief Summary
-----------------
Research has historically excluded the participation of transgender and gender-diverse people. The purpose of this research study is to find out about what goes into a transgender and gender-diverse youth's decision to participate in research. The results of this study will be used to improve access to research for transgender and gender-diverse youth and therefore, improve the representation of transgender and gender-diverse youth as research participants in research.

Official Title
-----------------
Research Participation With Transgender and Gender-Diverse Youth

Conditions
-----------------
Transgender Persons

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gender identity different then sex assigned at birth Between the ages 15-21 years Exclusion Criteria: Gender identity the same as their sex assigned at birth Younger than 15 years of age, and older than 21 years of age

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Survey<br>Participants will complete a one-time survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community | Other: Survey<br>* Survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative Assessment of Pediatric Research Participation in Transgender Youth | The outcome will be the responses (agree or disagree) to the different items in the Pediatric Research Participation measure. | through study completion, estimated to be 3 months | 
| Qualitative Assessment of Pediatric Research Participation in Transgender Youth | The investigators will implement qualitative analysis to explore transgender and gender-diverse youths experiences with research, and barriers and facilitators to participating in research. Specifically, the outcomes will be themes and supporting quotes. | through study completion, estimated to be 3 months |
To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian Patients

Study Overview
=================
Brief Summary
-----------------
To determine the accuracy of SCreening for Occult REnal Disease (SCORED) questionnaire for CKD risk among Asian Patients

Official Title
-----------------
A Real-World Multicentre Prospective Study to Determine the Accuracy of the SCORED (SCreening for Occult REnal Disease) Questionnaire for SCreening REnal Risk Early Against Nephropathy in Adult Population in Asia

Conditions
-----------------
Chronic Kidney Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and Specificity | The primary objective is to evaluate the accuracy of SCORED tool in identifying individuals at risk for the development of CKD in the Asian population. The primary outcomes, sensitivity, and specificity will be summarised using percentage and 95% confidence intervals to be measured at Baseline up to 6months after enrollment | 28 February 2024 |
Cognitive Behavioral Therapy on Adherence and Depression (CBT-AD) Among HIV/AIDS Patients

Study Overview
=================
Brief Summary
-----------------
Depression is highly comorbid with HIV/ AIDS and is associated with worse poor adherence to antiretroviral therapy (ART), and potentially to long-term immune functioning. Cognitive behavioral therapy may solve these problem.

Detailed Description
-----------------
Depression is highly comorbid with HIV/ AIDS and is associated with worse poor adherence to antiretroviral therapy (ART), and potentially to long-term immune functioning. Poor adherence decreases the benefits of ART as well as chances of prolonged survival. An intervention that integrates CBT for depression with a cognitive behavioral approach to adherence counseling (cognitive behavioral therapy intervention for adherence and depression (CBT-AD)) has been found to be effective in improving adherence and reducing depression in PLWH.

Official Title
-----------------
A Randomized Control Trial of Cognitive Behavioral Therapy on Adherence and Depression (CBT-AD) Among HIV/AIDS Patients on Follow up at Mattu Karl and Bedele Hospital, 2019

Conditions
-----------------
Depression, Medication Adherence

Intervention / Treatment
-----------------
* Behavioral: Cognitive Behavioral Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PLWHA who were 18 years old and above were included in the study Exclusion Criteria: PLWHA who were previously took CBT and participants with acute physical or mental disturbances were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention group<br>Taking Behavioral Therapy | Behavioral: Cognitive Behavioral Therapy<br>* The treatment will be offered to participants free of charge. Cognitive Behavioral Therapy (CBT) sessions will be delivered in a group therapy format and the sessions will be offered in successive weeks. The protocol will be then administered to the intervention group (in 8 groups over a period of six months, eight sessions, each of 30 minutes' length).<br>|
| No Intervention: Control group<br>Do not taking Behavioral Therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean score of Depression will change after intervention | Depression is measured by Patient Health Questionnaire (PHQ-9) Depression Scale. The minimum value is 0 and the maximum value is 27. The higher score mean worse outcome | Through study completion, an average of 1 yea |